BiotechTube
Danner Laboratory

Danner Laboratory

San Francisco, United States· Est.
dannerlab.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Danner Laboratory is a private, revenue-generating diagnostics company with roots dating to 1991, now operating from San Francisco with a focus on preventive oncology. Its core offering is the CTCReveal liquid biopsy test, which uses validated reagents and AI-powered imaging (CellSPOT-300) to detect circulating tumor cells from a simple blood draw. The company targets the growing liquid biopsy market by providing a minimally invasive alternative to tissue biopsies for cancer management, aiming to enable early detection and improve patient outcomes. It positions itself as a clinical laboratory service provider trusted by physicians for over two decades.

Oncology

Technology Platform

Proprietary CellBio™ technology for isolating/detecting Circulating Tumor Cells (CTCs), integrated with the AI-assisted digital imaging platform CellSPOT-300™ for enhanced accuracy in cytopathology and CTC analysis.

Opportunities

The rapid growth of the liquid biopsy market and the shift towards minimally invasive, repeatable cancer monitoring present a major expansion opportunity for CTCReveal.
Furthermore, integrating AI across its service portfolio can improve operational efficiency, reduce costs, and create a defensible technological moat in the competitive lab services sector.

Risk Factors

Intense competition from well-capitalized public companies in the liquid biopsy space poses a significant market penetration risk.
Additionally, achieving widespread clinical adoption and securing stable insurance reimbursement for the novel CTCReveal test are substantial commercial and regulatory hurdles.

Competitive Landscape

Danner Laboratory competes in the crowded liquid biopsy market against large, established players like Guardant Health (ctDNA) and diagnostic giants, as well as other CTC-focused companies. Its differentiation lies in the combination of its proprietary CellBio technology, AI-powered imaging, and an existing base of traditional cytopathology services, allowing it to offer a broader diagnostic menu to clinicians.

More companies in Diagnostics & Precision Medicine →More companies in United States →